A collaboration seen as a major step forward in the fight against Anti Microbial Resistance (AMR).

Background - Antibiotics are of utmost importance in the medical professions armoury against pathogenic infections, but each time they’re used in an attempt to kill infective bacteria we take a risk. Within a bacterial colony often there are ones that differ genetically from the rest. These carry resistant genes that prevent the antibiotics we use from killing them. If we kill the majority of susceptible bacteria but not the resistant ones, we make space for these resistant bacteria to become dominant. In other words, the antibiotic will no longer work against these resistant infective bacteria. This is also the case with disinfectant and antiseptic products. It seems, the more we clean with disinfectant, or the more we treat infections with antibiotics and antiseptic, the more dangerous the resistant bacteria can become. Bacteria build nests called biofilm on surfaces to protect themselves, for example, plaque on our teeth. When biofilms form, the efficacy of disinfectant, antiseptic and antibiotic technology reduces significantly. Biofilm dominated by resistant bacteria is disastrous.  We face therefore, a return to a pre antibiotic era where child birth, simple cuts or grazes, or stomach upsets could become fatal. We have to protect the antibiotics we have, ensuring their efficacy for as long as possible. We have a fight on our hands against resistant bacteria. We have a fight against AMR.


A major breakthrough in this fight is being worked on via a collaboration between Pruex Ltd from Carmarthenshire in Wales and Biowet Drwalew from Warsaw in Poland. Pruex, an innovative one health company, use detergents containing non infective bacteria to compete against infective ones in the environment and consistently demonstrate modulation of biofilm from being dominated by potentially pathogenic colonies of bacteria to non infective types. Biowet Drwalew manufacture antibiotics and have a long history and an established position in the market of veterinary medicinal products in Poland. Both organisations objectives align as they both want antibiotics to keep working for as long as possible without the threat of increasing AMR.


It’s known that biofilm on surfaces can contain resistant bacteria that can infect animals including humans. Biowet Drwalew manufacture antibiotics to World Health Organisation standards. Pruex products will be used to ensure the animals have clean water, a dry bed and clean air to breathe. By doing so, the aim is for the contents of the biofilm in the animal housing and water lines to change, increasing the dominance of non-infective bacteria and reducing the numbers of resistant bacteria. Reducing the number of resistant bacteria present will safeguard the use of antibiotics for future generations.


This work was presented by Aled Rhys Davies of Pruex on the 19th April at the prestigious 18th scientific buiatrics conference, specific and non-specific immunoprophylaxis of selected cattle diseases - new achievements and directions of development held at the Polish Buiatric Association, National Veterinary Institute, Puławy. His presentation caught the imagination of the attending veterinary delegation with the trade booth remaining busy over the two day event.


At the conference, Aled Rhys Davies, the founder of Pruex stated that “Nature often has the answer to our man made problems. Nature provides us with bacteria that can out compete the problematic resistant bacteria our medicines by default have encouraged. We have to be scientific in our approach so that we can harness such technology in the fight against AMR. We want to see antibiotic manufacturers continue to provide effective products and are excited that, along with the scientists and staff at Biowet Drwalew that we can conduct work to modulate the contents of biofilm in animal environments and water systems so that we can potentially enable antibiotics that currently are no longer effective to work once more. We have an opportunity to secure the future of prudent antibiotic use without the risk of building resistant bacterial biofilm”.